X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (28) 28
oncology (27) 27
humans (20) 20
colorectal cancer (12) 12
colorectal neoplasms - drug therapy (12) 12
female (12) 12
male (12) 12
mutation (12) 12
adult (10) 10
oxaliplatin (10) 10
aged (9) 9
bevacizumab (9) 9
middle aged (9) 9
animals (8) 8
cetuximab (8) 8
colorectal neoplasms - pathology (8) 8
metastasis (8) 8
1st-line treatment (7) 7
aged, 80 and over (7) 7
cancer (7) 7
colorectal neoplasms - genetics (7) 7
fluorouracil (7) 7
leucovorin (7) 7
panitumumab (7) 7
treatment outcome (7) 7
1506 (6) 6
antineoplastic agents - pharmacology (6) 6
chemotherapy (6) 6
metastatic colorectal cancer (6) 6
neoplasm metastasis (6) 6
patients (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
antineoplastic agents - therapeutic use (5) 5
cell line, tumor (5) 5
combination (5) 5
metastases (5) 5
regorafenib (5) 5
research (5) 5
safety (5) 5
therapy (5) 5
tumors (5) 5
antibodies, monoclonal - therapeutic use (4) 4
biomarkers (4) 4
care and treatment (4) 4
colorectal carcinoma (4) 4
drug therapy (4) 4
growth-factor receptor (4) 4
heterogeneity (4) 4
kras (4) 4
medical prognosis (4) 4
mice (4) 4
neoplasm staging (4) 4
open-label (4) 4
ras mutations (4) 4
survival (4) 4
young adult (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
breast-cancer (3) 3
cancer therapies (3) 3
cell proliferation - drug effects (3) 3
colorectal neoplasms - metabolism (3) 3
colorectal neoplasms - mortality (3) 3
disease models, animal (3) 3
dosage and administration (3) 3
efficacy (3) 3
everolimus (3) 3
gene expression regulation, neoplastic (3) 3
inhibitor (3) 3
irinotecan (3) 3
medicine & public health (3) 3
medicine, research & experimental (3) 3
molecular targeted therapy (3) 3
mutations (3) 3
neoplasms - drug therapy (3) 3
organoplatinum compounds - administration & dosage (3) 3
pharmacology & pharmacy (3) 3
phase-i (3) 3
phosphatidylinositol 3-kinases - antagonists & inhibitors (3) 3
placebo (3) 3
prognosis (3) 3
protein kinase inhibitors - pharmacology (3) 3
research article (3) 3
review (3) 3
settore med/06 - oncologia medica (3) 3
signal transduction - drug effects (3) 3
sorafenib (3) 3
survival rate (3) 3
targeted therapy (3) 3
tas-102 (3) 3
xenograft model antitumor assays (3) 3
acquired-resistance (2) 2
adenocarcinoma - drug therapy (2) 2
adenocarcinoma - pathology (2) 2
aflibercept (2) 2
alleles (2) 2
analysis (2) 2
anemia (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - pharmacology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 08/2018, Volume 128, Issue 9, pp. 3887 - 3905
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2019, Volume 20, Issue 6, pp. 849 - 861
Microsatellite-stable metastatic colorectal cancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus... 
DABRAFENIB | MEK | INHIBITION | ONCOLOGY | MICROSATELLITE INSTABILITY | TRAMETINIB | DEFICIENT | BRAF | COMBINATION | NIVOLUMAB | PD-1 | Analysis | Colorectal cancer | Metastasis
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2015, Volume 21, Issue 24, pp. 5499 - 5510
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 8, pp. 942 - 949
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2019, Volume 37, Issue 4, pp. 674 - 683
Background Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor that acts as an antitumor agent. This first-in-human study evaluated... 
Plocabulin | Phase I | Medicine & Public Health | PM060184 | Oncology | Solid tumors | Pharmacology/Toxicology | Microtubule inhibitor | First-in-human | LEUCOVORIN | OXALIPLATIN | CHEMOTHERAPY | POTENT ANTITUMOR-ACTIVITY | 5-FLUOROURACIL | THERAPY | ONCOLOGY | COLORECTAL-CANCER | METASTATIC BREAST-CANCER | PERIPHERAL NEUROPATHY | PHARMACOLOGY & PHARMACY | AGENTS | Neoplasms - metabolism | Peripheral Nervous System Diseases - chemically induced | Polyketides - pharmacokinetics | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Pyrones - blood | Young Adult | Antineoplastic Agents - adverse effects | Tubulin Modulators - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacokinetics | Tubulin Modulators - blood | Tubulin Modulators - adverse effects | Tubulin Modulators - pharmacokinetics | Treatment Outcome | Pyrones - administration & dosage | Neoplasms - drug therapy | Polyketides - adverse effects | Maximum Tolerated Dose | Pyrones - adverse effects | Polyketides - blood | Antineoplastic Agents - blood | Aged | Pyrones - pharmacokinetics | Polyketides - administration & dosage | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Drug therapy | Antineoplastic agents | Tumors | Schedules | Toxicity | Lung cancer | Clinical trials | Neuropathy | Metastases | Thymus | Anticancer properties | Infusion | Tubulin | Pain | Vomiting | Myelosuppression | Cervical carcinoma | Lung diseases | Non-small cell lung carcinoma | Fatigue | Nausea | Fatigue failure | Myalgia | Cervix | Patients | Studies | Inhibitors | Lysis | Antitumor activity | Titration | Parasympathetic nervous system | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 744 - 744
744 Background: Elevated neutrophil-to-lymphocyte (NLR) ratios may represent markers of a suboptimal host immune response to cancer and have been shown to... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 816 - 816
816 Background: Preclinical evidence suggests improved efficacy when combining trifluridine/tipiracil with oxaliplatin compared to each monotherapy (Nukatsuka,... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 496 - 496
496 Background: Sym004 consists of two anti-EGFR monoclonal antibodies (futuximab and modotuximab) directed against non-overlapping epitopes in the EGFR domain... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. TPS3626 - TPS3626
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2020, Volume 38, Issue 4_suppl, pp. 140 - 140
140 Background: Trifluridine/tipiracil (FTD/TPI) is approved for use in patients (pts) with pretreated mCRC. In vivo studies have shown an increase in... 
Journal Article